This paper compared the changes in miRNA profile of small extracellular vesicles (SEV) and large extracellular vesicles (LEVs) in four neurodegenerative diseases.
Different miRNA Profiles in Plasma Derived Small and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases.
Sproviero D, Gagliardi S, Zucca S, Arigoni M, Giannini M, Garofalo M, Olivero M, Dell'Orco M, Pansarasa O, Bernuzzi S, Avenali M, Cotta Ramusino M, Diamanti L, Minafra B, Perini G, Zangaglia R, Costa A, Ceroni M, Perrone-Bizzozero NI, Calogero RA, Cereda C
Purpose
Conclusion
For each disease state, upregulated and downregulated miRNAs in SEVs and LEVs were found when compared to those from healthy patients and a percentage of these were found to be deregulated in both SEVs and LEVs. The percentage of miRNAs that were upregulated or downregulated in both SEVs and LEVs depended on disease state. Principal component analysis (PCA) based on deregulated miRNA in SEVs showed no overlap between the control group and the four diseases and while some clustering was observed between the diseases, there was some overlap. PCA of miRNAs differentially expressed in LEVs showed some overlap between specimens from healthy patients and those with disease and some overlap among the four disease states but no distinct clusters. There were six miRNAs in SEVs and seven miRNAs in LEVS that were found to be deregulated in all four neurological diseases compared to healthy controls. The authors identified pathways enriched for the miRNAs deregulated in all four neurological diseases and in each disease.
Studies (1)
Purpose
This study compared the changes in miRNA profile of small extracellular vesicles (SEV) and large extracellular vesicles (LEVs) in four neurodegenerative diseases. Sodium citrate blood was obtained from six patients with Alzheimer’s disease (AD), nine patients with Parkinson’s disease (PD), six patients with Amyotrophic Lateral Sclerosis (ALS), and nine patients with Fronto-Temporal Dementia (FTD) as well as from six age-matched healthy controls. Platelet-free plasma was centrifuged at 20,000 x g for 1 h and the pellet washed and filtered through a 0.2 µm filter to obtain LEVS. SEVs were obtained by centrifugation at 100,000 x g for 1 h at 4°C and washed in PBS. Isolation of SEVs and LEVs was confirmed by Western Blot analysis, transmission electron microscopy, and nanoparticle tracking analysis. RNA was extracted from LEVs and SEVs using the Qiagen miRNeasy Mini Kit and sequencing libraries were constructed using the NEBNext Kit. The libraries were sequenced on an Illumina NextSeq500. Differentially expressed miRNAs were identified using a minimum fold change of 2 and a false discovery rate threshold of <0.1 compared to healthy controls. Enriched pathways were identified using miRWalk.
Summary of Findings
For each disease state, upregulated and downregulated miRNAs in SEV and LEVs were found when compared to those from healthy patients. For example, 17 miRNAs were upregulated and 16 downregulated in SEVs and 10 miRNAs upregulated and three downregulated in LEVs in patients with Alzheimer’s disease compared to those from healthy controls. The total number miRNAs deregulated was 33, 88, 109, and 104 in SEVs and 13, 130, 197, and 109 in LEVs in patients with AD, PD, ALS, and FTD, respectively. Using these miRNAs, the authors found pathways affected in each of the four diseases. The percentage of miRNAs that were deregulated in both SEVs and LEVs depended on disease state, with 6, 34, 67, and 34 miRNAs differentially expressed in both SEVs and LEVs of patients with AD, PD, ALS, and FTD, respectively. The affected miRNAs in SEVs did not show overlap in PCA between control and any of the four disease states, but some overlap between the diseases was observed. Six miRNAs (hsa-miR-133a-3, hsa-miR-543, hsa-miR-4451, hsa-miR-6889-5p, hsa-miR-4781-3p, and hsa-miR-323b-3p) were identified to be differentially expressed in SEVs of all four diseases compared to healthy controls. These miRNAs were found to be enriched in the ubiquitin-mediated proteolysis, MAPK signaling, and toll-like receptor signaling pathways. While PCA of miRNAs differentially expressed in LEVs showed no clear subclusters among the four disease states and some overlap between specimens from healthy patients and those with neurological disease, seven miRNAs (hsa-miR-1262, hsa-miR-3152-3p, hsa-miR-7856-5p, hsa-miR-365a-5p, hsa-miR-4433b-5p, hsa-miR-6068, and hsa-miR-767-3p) were found to be differentially expressed in LEVs in all four diseases compared to healthy controls. These seven miRNAs were enriched in neurotrophin signaling, MAPK signaling, gycosphingolipid biosynthesis, and Ras signaling pathways.
Biospecimens
FluidPlasmaPreservation Types
None (Fresh)Diagnoses
Amyotrophic Lateral SclerosisParkinson's DiseaseAlzheimer's DiseaseOther diagnosesNormalPlatforms
RNANext generation sequencingPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Alzheimer’s diseaseAmyotrophic Lateral SclerosisFronto-Temporal DementiaHealthParkinson’s diseaseBiospecimen Aliquots and Components Blood and blood products Large extracellular vesiclesPlasma vesiclesSmall extracellular vesicles